Cirtemo, which incorporated University of South Carolina-born MagAssemble, has been acquired by Thorlabs for an unspecified amount.

Edtech provider Renaissance has bought UM's early years education assessment provider Early Learning Labs, vindicating twenty years of government-funded research.

Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The We Company, valued at $47bn as of January, confidentially filed for an IPO in December that would provide exits for SoftBank and Jin Jiang International.

Axiata Digital will divest a 30 company-strong corporate venturing portfolio valued at $140m to Pegasus 7 Ventures, an investment firm run by one of its ex-executives.

Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.

The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.

Media group Nikkei has bought a controlling interest in corporate-backed financial news publication DealStreetAsia, allowing Singapore Press Holdings to sell shares.

SoftBank Vision Fund owns more than 7% of the enterprise messaging platform developer, which could list at a valuation near $17bn.

Uber is set to raise $7.9bn to $9bn if it floats within its range, while PayPal has agreed to invest another $500m through a private placement.